BEAM:NSD-Beam Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 73.49

Change

-10.27 (-12.26)%

Market Cap

USD 5.53B

Volume

2.37M

Average Target Price

USD 103.50 (+40.84%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts. Address: 26 Landsdowne Street, Cambridge, MA, United States, 02139

Company Website : http://www.beamtx.com

Address : 26 Landsdowne Street, Cambridge, MA, United States, 02139

Employees : 166

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 126.90

Short Ratio : 5.13

52 Week Low : 13.00

Shorted Shares : 5,337,846

200 Day Moving Average : 58.22

Shorted Shares Previous Month : 5,581,056

50 Day Moving Average : 102.00

Shares Held By Insiders : 168.43%

Short Percentage : 9.00%

Shares Held by Institutions : 65.51000000000001%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.65 (-0.31%)

 USD54.19B 20.26 15.08
MRNA Moderna, Inc

+1.08 (+0.82%)

 USD52.46B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

+2.65 (+0.59%)

 USD47.86B 14.64 11.87
ALXN Alexion Pharmaceuticals, Inc

+0.27 (+0.18%)

 USD32.58B 54.48 33.22
BGNE BeiGene, Ltd

-15.33 (-5.03%)

 USD29.17B N/A N/A
SGEN Seagen Inc

-2.48 (-1.68%)

 USD26.80B 43.90 37.70
RPRX Royalty Pharma plc

-1.23 (-2.82%)

 USD26.45B 22.60 14.17
BNTX BioNTech SE

-2.10 (-2.16%)

 USD25.28B -99,999.99 N/A
GMAB Genmab A/S

-1.63 (-5.01%)

 USD22.05B 26.59 3.17
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing BEAM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.34% 17% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.34% 17% F 10% F
Trailing 12 Months  
Capital Gain 208.65% 92% A- 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 208.65% 92% A- 92% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 19.69% 59% F 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.69% 58% F 73% C
Risk Return Profile  
Volatility (Standard Deviation) 80.44% 32% F 16% F
Risk Adjusted Return 24.48% 55% F 50% F
Market Capitalization 5.53B 92% A- 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 91% A- 95% A
Price/Book Ratio 26.02 8% F 7% F
Price / Cash Flow Ratio -76.87 94% A 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -77.71% 40% F 15% F
Return on Invested Capital -62.45% 45% F 15% F
Return on Assets -32.96% 37% F 11% F
Debt to Equity Ratio 4.37% 69% D+ 83% B
Technical Ratios  
Short Ratio 5.13 33% F 21% F
Short Percent 12.68% 19% F 14% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector